Why Partner with Specialised Therapeutics?
We take care of your product as if it were our own. We manage the regulatory and reimbursement complexities to ensure our partner’s drugs are commercialised to the highest standards.
Track Record
Specialised Therapeutics has a strong track record championing partner products from pre-registration through to full commercialisation.
Regional Expertise
Our regulatory and reimbursement teams bring deep experience navigating complex registration
and reimbursement pathways in Australia, New Zealand and across South East Asia.
Experienced Teams
Specialised Therapeutics employs highly-skilled pharmaceutical executives with wide industry experience gained at some of the world’s largest pharma companies across numerous speciality therapeutic areas.
Meeting the unmet needs
of patients in Australia,
New Zealand and
Southeast Asia
What We Do
Agreements
We are open to joint ventures, typical royalty and milestone-based licensing agreements or other creative, mutually beneficial partnering opportunities.
Regulatory
Our regulatory team manages complex submission processes in all key markets, including Orphan and Fast-Track designations.
Commercialisation
Our commercial team achieves rapid market penetration and leadership of portfolio therapies.
Reimbursement Expertise
Our experienced teams navigate reimbursement applications and processes for pharmaceutical products, companion diagnostics and other medical technologies.
Access Programs
We successfully launch and manage Named Patient Access Programs in our regions, enabling patients early or compassionate access to new therapies.
Our Partners
We collaborate with international partner companies , championing their speciality products from pre-registration through to full commercialisation
- February 2008
- January 2009
- January 2012
- June 2012
- January 2014
- January 2014
- April 2014
- February 2016
- November 2017
- December 2019
- October 2020
- October 2021
-
ST – Abraxis Bioscience Partnership
ST - Abraxis Bioscience PartnershipST acquires exclusive Australian rights to market foundation product ABRAXANE® (nanoparticle-albumin bound paclitaxel) -
ST-Helsinn Healthcare Partnership
ST-Helsinn Healthcare PartnershipST partners with privately-owned Swiss pharma company Helsinn Healthcare, acquiring exclusive rights to anti-nausea drug ALOXI® (palonesetron) in Australia and NZ -
Photonamic GmbH and co Partnership
Photonamic GmbH and co PartnershipST acquires exclusive rights to market brain tumour visualisation technology GLIOLAN® (animolivulenic acid hcl) in Australia, New Zealand -
Optimer Pharmaceuticals, Inc. Partnership
Optimer Pharmaceuticals, Inc. PartnershipST partners with US-based biopharmaceutical company Optimer Pharmaceutics, Inc. acquiring exclusive rights to market DIFICID® (fidaxomicin) in Australia and New Zealand -
Genomic Health Partnership
Genomic Health PartnershipST partners with US company Genomic Health to market the Oncotype DX Breast Recurrence Score® test -
Ariad Pharmaceuticals Partnership
Ariad Pharmaceuticals PartnershipUS-based Ariad Pharmaceuticals grants ST exclusive rights to market ICLUSIG® (ponatinib) in Australia, NZ -
Alimera Sciences, Inc. Partnership
Alimera Sciences, Inc. PartnershipST partners with US-based Alimera Sciences, Inc. for exclusive rights to distribute ILUVIEN® (190 micrograms fluocinolone acetonide intravitreal implant in applicator) in Australia and New Zealand -
ST PharmaMar SA Partnership
ST PharmaMar SA PartnershipST partners with Spanish company PharmaMar SA, acquiring exclusive rights to APLIDIN® (plitidepsin) in Australia, New Zealand and South East Asia -
ST – Puma Biotechnology Partnership
ST – Puma Biotechnology PartnershipST partners with US-based Puma Biotechnology, acquiring exclusive rights to market NERLYNX® (neratinib) in Australia, NZ and South-East Asia -
ST – Onconova Therapeutics Partnership
ST – Onconova Therapeutics PartnershipST partners with US-based Onconova Therapeutics, acquiring exclusive rights to market Rigosertib in Australia and New Zealand -
ST-Deciphera Pharmaceuticals Partnership
ST-Deciphera Pharmaceuticals PartnershipST partners with US based Deciphera Pharmaceuticals, acquiring exclusive rights to market QINLOCK® (ripretinib) in Australia, NZ and South East Asia -
ST-Incyte Partnership Agreement
ST-Incyte Partnership AgreementST partners with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios
Media
Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn Group
Melbourne, Australia and Lugano, Switzerland, 10 August 2011: Melbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its ...
Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a ...
Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients
Melbourne, Australia January 7, 2014: Australian women will potentially have greater access to the only genomic test validated to ...
ARIAD Announces Commercial Agreement for ICLUSIG® (ponatinib) in Australia
Melbourne, Australia January 28, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty ...
Specialised Therapeutics Asia to Distribute Novel Multiple Myeloma Drug APLIDIN® in South East Asia, Australia and New Zealand
SINGAPORE and MELBOURNE, Australia, Feb. 2, 2016 /PRNewswire/ — International biopharmaceutical company Specialised Therapeutics Asia (ST Asia) will supply ...
Aeterna Zentaris and Specialised Therapeutics Asia Sign Exclusive License Agreement for the Potential Marketing of Zoptrex™ in Australia and New Zealand
Charleston, South Carolina and Singapore, October 12, 2016: Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and ...